Stage 2 (Conversion): Released GH travels to the liver to be converted into IGF-1 (the actual builder)
These include labeling, claims, manufacturing, and documentation
Additionally, in vivo validation and clinical reproducibility are limited
Low exploratory: 1 nmol/kg subcutaneous (produces a measurable LH pulse within 30 minutes) Moderate support: 3 to 5 nmol/kg subcutaneous, daily or every other day, for 2 to 4 weeks Two forms exist: kisspeptin-54 (full-length, longer-acting, better studied in clinical trials) and kisspeptin-10 (C-terminal fragment, shorter-acting)
Patients often tolerate smaller meals, slower eating, lean protein, bland foods, and lower-fat meals better during nausea, but individualized guidance matters
Microsc Microanal (2017) 23:100212